Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,474 Financial Services 1,896 Healthcare 1,114 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 336 Consumer Defensive 248 Communication Services 212 Utilities 185 Energy 165 Real Estate 81

115 stocks · page 1 of 2

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

AGILENT TECHNOLOGIES, INC.

Deeply overvalued

Premium +155% Return to IV: -60.8%

Owner yield 2.6% 10-yr IRR -1.0% · steady

Market implies +16.5%/yr vs model +4.7% · above model

Model IV$208.02

Premium +27% Return to IV: -21.3%

Owner yield 3.9% 10-yr IRR 3.7% · steady

Market implies +7.0%/yr vs model +4.5% · in line

ABBOTT LABORATORIES

Model IV$104.52

Discount 1% Return to IV: +1.5%

Owner yield 3.5% 10-yr IRR 2.0% · steady

Market implies +3.4%/yr vs model +4.1% · in line

Akari Therapeutics Plc

Deeply undervalued

Model IV$213.61

Discount 70% Return to IV: +229.3%

Owner yield 6.2% 10-yr IRR 18.2% · grower

Market implies +1.0%/yr vs model +21.9% · below model

ALIGN TECHNOLOGY INC

Deeply overvalued

Premium +167% Return to IV: -62.6%

Owner yield 5.4% 10-yr IRR 8.8% · steady

Market implies +18.9%/yr vs model +5.7% · above model

ALNYLAM PHARMACEUTICALS, INC.

Model IV$347.64

Discount 30% Return to IV: +42.3%

Market implies -10.2%/yr vs model +44.8% · below model

Deeply overvalued

Model IV$155.98

Premium +55% Return to IV: -35.3%

Owner yield 3.0% 10-yr IRR 3.0% · moderate

Market implies +12.6%/yr vs model +8.2% · above model

Model IV$452.91

Discount 13% Return to IV: +15.2%

Owner yield 4.0% 10-yr IRR 8.8% · moderate

Market implies +6.7%/yr vs model +10.7% · below model

Apogee Therapeutics, Inc.

Ascendis Pharma A/S

Deeply overvalued

Premium +93% Return to IV: -48.1%

Owner yield 6.2% 10-yr IRR 8.7% · steady

Market implies +11.9%/yr vs model +3.0% · above model

Axsome Therapeutics, Inc.

Market implies +17.8%/yr vs model +15.0% · in line

ASTRAZENECA PLC

BAXTER INTERNATIONAL INC

Deeply overvalued

Premium +346% Return to IV: -77.6%

Owner yield 6.2% 10-yr IRR 8.8% · steady

Market implies +23.6%/yr vs model +3.0% · above model

BridgeBio Pharma, Inc.

Deeply overvalued

Premium +276% Return to IV: -73.4%

Market implies +18.1%/yr vs model +50.0% · below model

Biodexa Pharmaceuticals Plc

Market implies +150.0%/yr vs model +15.0% · above model

BECTON DICKINSON & CO

Owner yield 5.1% 10-yr IRR 7.7% · steady

Market implies +3.5%/yr vs model +5.4% · in line

Model IV$249.04

Discount 12% Return to IV: +13.7%

Owner yield 6.3% 10-yr IRR 8.8% · steady

Market implies +1.0%/yr vs model +3.0% · in line

BIO-RAD LABORATORIES, INC.

Deeply overvalued

Model IV$254.24

Premium +48% Return to IV: -32.6%

Owner yield 2.9% 10-yr IRR 0.6% · steady

Market implies +9.7%/yr vs model +5.5% · above model

BIOMARIN PHARMACEUTICAL INC

Deeply undervalued

Discount 36% Return to IV: +56.0%

Owner yield 3.4% 10-yr IRR 8.3% · grower

Market implies +4.8%/yr vs model +13.5% · below model

BRISTOL MYERS SQUIBB CO

Deeply undervalued

Model IV$174.33

Discount 64% Return to IV: +178.4%

Owner yield 10.3% 10-yr IRR 19.2% · moderate

Market implies -7.6%/yr vs model +6.1% · below model

Market implies +32.2%/yr vs model +9.2% · above model

BOSTON SCIENTIFIC CORP

Deeply undervalued

Model IV$105.68

Discount 59% Return to IV: +141.7%

Owner yield 4.1% 10-yr IRR 10.6% · grower

Market implies -0.5%/yr vs model +12.8% · below model

BrightSpring Health Services, Inc.

Deeply overvalued

Premium +62% Return to IV: -38.3%

Market implies +19.3%/yr vs model +16.1% · above model

BrightSpring Health Services, Inc.

Model IV$187.63

Discount 1% Return to IV: +1.5%

Market implies -2.8%/yr vs model +18.7% · below model

Deeply overvalued

Premium +342% Return to IV: -77.4%

Owner yield 1.5% 10-yr IRR -7.5% · steady

Market implies +25.0%/yr vs model +4.5% · above model

Market implies +32.9%/yr vs model +17.0% · above model

COOPER COMPANIES, INC.

Premium +22% Return to IV: -18.2%

Owner yield 2.9% 10-yr IRR 3.3% · moderate

Market implies +10.2%/yr vs model +9.2% · in line

CORCEPT THERAPEUTICS INC

Market implies +32.3%/yr vs model +20.1% · above model

QUEST DIAGNOSTICS INC

Deeply undervalued

Model IV$352.30

Discount 30% Return to IV: +43.9%

Owner yield 3.8% 10-yr IRR 4.7% · moderate

Market implies +0.9%/yr vs model +6.5% · below model

DANAHER CORP /DE/

Deeply overvalued

Model IV$130.15

Premium +66% Return to IV: -39.7%

Owner yield 3.5% 10-yr IRR 1.8% · steady

Market implies +9.9%/yr vs model +3.7% · above model

Deeply undervalued

Model IV$590.72

Discount 69% Return to IV: +224.0%

Owner yield 10.3% 10-yr IRR 22.5% · moderate

Market implies -6.6%/yr vs model +9.9% · below model

Premium +16% Return to IV: -13.8%

Owner yield 2.1% 10-yr IRR 3.2% · grower

Market implies +14.7%/yr vs model +16.6% · in line

Encompass Health Corp

Model IV$134.43

Discount 10% Return to IV: +10.6%

Owner yield 2.9% 10-yr IRR 3.9% · moderate

Market implies +6.8%/yr vs model +10.2% · below model

Elanco Animal Health Inc

Deeply overvalued

Premium +348% Return to IV: -77.7%

Owner yield 2.4% 10-yr IRR -3.1% · steady

Market implies +23.9%/yr vs model +3.0% · above model

ENSIGN GROUP, INC

Deeply undervalued

Model IV$459.50

Discount 62% Return to IV: +163.4%

Market implies -0.2%/yr vs model +15.4% · below model

Edwards Lifesciences Corp

Deeply overvalued

Premium +74% Return to IV: -42.4%

Owner yield 1.5% 10-yr IRR -5.6% · moderate

Market implies +13.2%/yr vs model +7.5% · above model

Deeply undervalued

Discount 35% Return to IV: +54.8%

Owner yield 3.8% 10-yr IRR 11.1% · grower

Market implies +6.0%/yr vs model +15.2% · below model

Fresenius Medical Care AG

Deeply undervalued

Model IV$106.03

Discount 79% Return to IV: +377.2%

Owner yield 17.4% 10-yr IRR 29.7% · moderate

Market implies -15.1%/yr vs model +6.5% · below model

Premium +22% Return to IV: -17.7%

Owner yield 6.7% 10-yr IRR 10.0% · steady

Market implies +5.4%/yr vs model +3.3% · in line

GE HealthCare Technologies Inc.

Deeply overvalued

Premium +37% Return to IV: -26.8%

Owner yield 5.4% 10-yr IRR 8.9% · steady

Market implies +9.2%/yr vs model +5.9% · above model

Guardant Health, Inc.

Deeply overvalued

Premium +522% Return to IV: -83.9%

Market implies +21.0%/yr vs model +27.3% · below model

GILEAD SCIENCES, INC.

Model IV$157.63

Discount 4% Return to IV: +4.7%

Owner yield 4.8% 10-yr IRR 6.2% · steady

Market implies +3.2%/yr vs model +4.3% · in line

HALOZYME THERAPEUTICS, INC.

Deeply undervalued

Model IV$316.93

Discount 65% Return to IV: +184.4%

Owner yield 3.6% 10-yr IRR 10.3% · grower

Market implies +5.2%/yr vs model +25.0% · below model

HCA Healthcare, Inc.

Deeply undervalued

Model IV$1,284.29

Discount 67% Return to IV: +201.5%

Owner yield 5.9% 10-yr IRR 14.7% · moderate

Market implies -4.5%/yr vs model +11.6% · below model

IDEXX LABORATORIES INC /DE

Deeply overvalued

Model IV$231.99

Premium +122% Return to IV: -55.0%

Owner yield 2.1% 10-yr IRR 0.1% · moderate

Market implies +19.0%/yr vs model +9.9% · above model

Market implies +19.7%/yr vs model +3.0% · above model

Deeply overvalued

Premium +414% Return to IV: -80.6%

Market implies +13.7%/yr vs model +33.9% · below model

INTUITIVE SURGICAL INC

Deeply overvalued

Model IV$135.74

Premium +196% Return to IV: -66.2%

Owner yield 1.0% 10-yr IRR -5.3% · grower

Market implies +25.2%/yr vs model +13.7% · above model

Jazz Pharmaceuticals plc

Deeply undervalued

Model IV$483.86

Discount 50% Return to IV: +100.4%

Owner yield 8.4% 10-yr IRR 18.2% · moderate

Market implies -1.7%/yr vs model +8.9% · below model

JOHNSON & JOHNSON

Model IV$223.02

Premium +21% Return to IV: -17.2%

Owner yield 2.8% 10-yr IRR 1.4% · moderate

Market implies +8.5%/yr vs model +7.3% · in line

Keysight Technologies, Inc.

Deeply overvalued

Premium +307% Return to IV: -75.4%

Owner yield 1.9% 10-yr IRR -3.4% · moderate

Market implies +25.7%/yr vs model +6.4% · above model

Longeveron Inc.

Market implies +150.0%/yr vs model +14.1% · above model

LABCORP HOLDINGS INC.

Model IV$397.08

Discount 19% Return to IV: +23.7%

Owner yield 3.9% 10-yr IRR 6.2% · moderate

Market implies +3.6%/yr vs model +7.8% · below model

Deeply overvalued

Model IV$748.36

Premium +56% Return to IV: -35.8%

Market implies +20.5%/yr vs model +19.2% · in line

MADRIGAL PHARMACEUTICALS, INC.

Deeply overvalued

Model IV$135.61

Premium +285% Return to IV: -74.0%

Market implies +10.2%/yr vs model +15.0% · below model